14 Publicly Traded Companies Developing Longevity Therapeutics

by BiopharmaTrend 

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   740    Comments 0

The longevity industry has been growing throughout the past decades, attracting more attention to the healthy aging process and searching for solutions for chronic diseases, including neurodegenerative diseases. The studies in the longevity field aim to not only prolong the expected life span but to improve its quality, using various approaches, including AI for target/biomarker discovery and validation, as well as the optimization of preclinical and clinical trials.

The interactive analytical report Companies Developing Anti-Aging Drugs and Diagnostics Tools provides detailed information about 122 current players in the field, highlighting the results of clinical trials, intellectual property rights, and more. Several of these companies managed to build sophisticated drug discovery platforms and advance their drug candidates into clinical trials while performing successful IPOs. Below we summarize some of the public companies developing anti-aging therapeutics.

Disclaimer: This post is not investment advice of any kind; it is for informational purposes only. Neither BPT Analytics Ltd nor the authors of this post endorse or recommend any particular stocks or investment opportunities. Consult relevant professional service providers for any investment decisions at all times.

 

AgeX Therapeutics, Inc. (NYSE American: AGE)

US-based AgeX Therapeutics was founded in 2017 and has grown as a biotech company focusing on therapeutics for age-related diseases. The company went public in 2018 by distributing approximately 12.7 million shares to BioTime shareholders.

AgeX owns several proprietary technologies and platforms to generate highly defined, universal, allogeneic pluripotent stem cell-derived cells for various applications. Currently, they have three drug candidates in the preclinical studies, aiming to fight type II diabetes, cardiac ischemia, and generally aged tissues affected with degenerative diseases.

The most recent news from the end-November 2022 announced that AgeX was granted an extension of time to regain compliance with the Exchange’s continued listing standards, meaning that AgeX must comply with the financial requirements by May 17, 2023, or the company would risk running into Exchange’s delisting proceedings.

 

Athersys, Inc. (NASDAQ: ATHX)

Athersys is a US-based company founded in 1995 which developed a strong focus on regenerative medicine. The company went public in November 2022 with a $5.5 million IPO.

Their proprietary platform, MultiStem is cell therapy, an allogeneic stem cell product, which can treat multiple indications in the neurological, inflammatory, immune, and cardiovascular disease areas. Currently, Athersys has 12 pipelines, of which 5 are in the clinical stage.  The most advanced program is in phase 3 clinical trials focused on treating ischemic stroke.

 

Biophytis, S.A. (NASDAQ: BPTS)

Biophytis is a French biotech company founded in 2006. They aim to slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19.

Biophytis closed a $20.1 million IPO in February 2021.

Their most advanced clinical program is currently in phase III, evaluating  Sarconeos (BIO101) as a treatment to prevent further respiratory deterioration in patients with acute respiratory failure associated with COVID-19. The same drug candidate is also evaluated in phase II clinical trials for sarcopenia, an age-related skeletal muscle degeneration.

Continue reading

This content available exclusively for BPT Mebmers

Share this:              

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *

SHARE